New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring

Stock Information for BioXcel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioXcel Therapeutics Inc.

CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.